Get App

BioNTech/Pfizer expect new variant impact data 'within 2 weeks'

Germany's BioNTech is studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.
  • Updated On Nov 27, 2021 at 06:38 AM IST
Germany's BioNTech said Friday it was studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.

"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally," a BioNTech spokesperson said.
  • Published On Nov 27, 2021 at 06:37 AM IST

Comments

comment
What are your thoughts?
Comment Now Read Comment (1)

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!